



MAIPA Assay

REF 900006 and 900016

Monoclonal Antibody-specific Immobilization of Platelet Antigen

Antibody Screening and Identification Kit

ANTIBODIES TO PLATELETS GIVE RISE TO FOUR CLINICAL DISORDERS:

- Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
- Post-transfusion purpura (PTP)
- Platelet refractoriness (PR)
- Immune thrombocytopenia (ITP)

CE MARKED IVDR (EU) 2017/746

SCREENING AND IDENTIFICATION KIT

CLINICAL DISORDERS: FNAIT, PTP, PR and ITP

AVAILABLE FORMAT: 96T and 480T



EN ISO 13485:2016 • CERTIFIED COMPANY

Advanced Practical Diagnostics BV
Raadsheerenstraat 3 • 2300 Turnhout, Belgium
T +32 14 45 35 99 • admin@apdia.be • www.apdiagroup.com

ANTIBODIES TO PLATELETS GIVE RISE TO FOUR CLINICAL DISORDERS:

- **Fetal and neonatal alloimmune thrombocytopenia (FNAIT)**
- **Post-transfusion purpura (PTP)**
- **Platelet refractoriness (PR)**
- **Immune thrombocytopenia (ITP)**

● **FNAIT** can occur during pregnancy, when a mother gets immunized against platelet alloantigens present on fetal platelets. This may occur when fetal platelet antigens inherited from the father differ from and are not present on the mother's platelets. Because of this immunization, IgG alloantibodies against the paternal platelet antigen are produced by the mother and then transferred through a neonatal Fc-receptor (FcRn)-mediated mechanism, crossing the placenta to enter the fetal circulation. The maternal alloantibodies can bind to the fetal platelets and cause immune destruction of platelets in utero. The ensuing fetal thrombocytopenia may lead to bruising, (intracranial) hemorrhage with possible associated neurological damage or even death in severe cases. In Caucasian populations, FNAIT is most commonly related to anti-HPA-1a antibodies (approx. 85 – 90 % of cases) and to a lesser extent to anti-HPA-5b antibodies.

● **PTP** is a rare transfusion reaction that may develop within two weeks after a transfusion of any blood product containing platelets (e.g. RBC concentrates) and can present as a severe thrombocytopenia complicated with bleeding and hemorrhage which can sometimes be life-threatening. It is most commonly identified in middle-aged multiparous women. All patients have had a previous sensitization to HPA alloantigens that they lack during a previous pregnancy or blood transfusion. The clinical condition of PTP is then mediated during a next transfusion as an antibody response against such platelet alloantigens in a second challenge (re-sensitization) to incompatible transfused platelets bearing the implicated HPA antigen(s).

As a result, the transfused platelets are destroyed by the produced alloantibodies, causing a sudden fall in platelet count. The most commonly implicated antibody is HPA-1a, made by HPA-1bb patients/recipients. Paradoxically, the patient's own platelets are simultaneously destroyed through a not yet fully understood mechanism.

PTP is considered a self-limited disease with recovery of platelet counts in approximately 20 days. Treatment with IVIG (Intravenous Immunoglobulin) is regarded as the most optimal first-line therapy.

● **PR** is defined as a condition of inadequate increment in platelet count following transfusion of random ABO identical donor platelets. It is a common complication in patients receiving multiple platelet transfusions. This clinical condition may develop when patients become immunized against HLA Class I antigens and make anti-HLA alloantibodies, leading to febrile, nonhemolytic transfusion reactions. Some patients may also develop anti-HPA antibodies with anti-HPA-5b the most common specificity. Because immunized patients often possess antibodies against different HLA Class I antigens, it can be difficult to find compatible platelets for transfusion support.

● **ITP** is also known as Idiopathic Thrombocytopenic Purpura. It is an autoimmune disease characterized by immune-mediated platelet destruction and inhibition of the platelet production. Affected patients make autoantibodies which destroy the patient's own (autologous) platelets. In most cases autoantibodies against the platelet glycoprotein complexes GPIIb/IIIa and GPIb/IX are involved. Children may develop ITP after a viral infection and usually will recover without treatment. In adults, the disorder may be triggered by infection with HIV, hepatitis or Helicobacter pylori and may be a long term disease.

DETECTION AND IDENTIFICATION OF ANTI-PLATELET ANTIBODIES WITH APDIA STANDARDIZED PLATELETS

can be done with several techniques such as immunoblotting, immunoprecipitation, platelet immunofluorescence tests (PIFT) or the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay. MAIPA is considered to be the gold standard method for platelet antibody detection. It requires the use of human thrombocytes typed for the important platelet antigens frequently observed in HPA immunizations: primarily the HPA-1, -3, -5 and secondly the HPA-2, -4, -6 and -15 antigens. The HPA-1 and HPA-3 platelet antigens are located on glycoprotein GpIIb/IIIa (CD41/CD61) fibrin receptor, while GpIb/IX (CD49b/CD31) collagen receptor bears the HPA-5 system and GpIb/IX (CD42a/CD42b) platelet receptor for von Willebrand factor also carries relevant antigens. Besides the platelet specific glycoproteins, the HLA class I found on platelets and nucleated cells is also a major allo-antigen giving rise to antibodies reacting with HLA on the platelets.

Detection and identification of allo- or auto-antibodies against platelets is indispensable for a targeted therapy of FNAIT, PTP, PR and ITP in platelet transfusions.

ADVANTAGES OF THE COMPLETE KIT

The apDia ready-to-use human Platelet-Antibody Screening Cells & Platelet-Antibody Identification Panel Cells are manufactured by employing a special proprietary production process. The standardized antibody screening panel allows the sensitive detection of anti-HPA antibodies, while the platelet antibody identification panel offers the ability to reliably identify the antibodies.

These reagents are advantageous for standardization, handling and workflow organization in the platelet immunology laboratory. The use of well-characterized thrombocytes offers the ability to standardize the MAIPA: the apDia thrombocyte reagents allow the use of typed cells expressing even rare antigen combinations such as HPA-1 (a-,b+) [2.5%] and HPA-5 (a-,b+) [less than 1%] for an extended period of time.

As the sole CE-marked MAIPA Assay kit available on the market, it stands out as a valuable alternative for laboratories currently reliant on Laboratory Developed Test (LDT) assays. This becomes particularly crucial in light of the impending restriction outlined in the European Regulation IVDR 2017/746.

| Donor | Blood group | HPA-1a | HPA-1b | HPA-2a | HPA-2b | HPA-3a | HPA-3b | HPA-4a | HPA-4b | HPA-5a | HPA-5b | HPA-6a | HPA-6b | HPA-15a | HPA-15b |
|---------------------------|-------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---------|---------|
| Screening cells | 0 | + | + | + | + | + | + | + | - | + | + | + | - | (+) | (+) |
| Identification platelet 1 | 0 | - | + | + | - | + | - | + | - | - | - | + | - | (+) | (+) |
| Identification platelet 2 | 0 | - | + | + | - | + | - | + | - | + | + | + | - | (+) | (-) |
| Identification platelet 3 | 0 | - | + | + | + | - | + | + | - | + | + | + | - | (-) | (+) |
| Identification platelet 4 | 0 | + | - | + | - | - | + | + | - | - | - | + | - | (-) | (+) |
| Identification platelet 5 | 0 | + | - | + | + | + | - | + | - | + | + | + | - | (+) | (-) |
| Identification platelet 6 | 0 | + | - | + | - | - | + | + | - | + | + | + | - | (+) | (+) |

DONOR AND ANTIGENS OF EACH IDENTIFICATION CELL PANEL MAY DIFFER FROM LOT TO LOT.

BIBLIOGRAPHY

1. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. *Blood*. 1987 Dec; 70(6):1722-6.
2. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation. Campbell K, Rishi K, Howkins G, Gilby D, Mushens R, Ghevaert C, Metcalfe P, Ouweland WH, Lucas G. *Vox Sang*. 2007 Nov; 93(4):289-97.
3. Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art. Porcelijn L, Huiskes E, Oldert G, Schipperus M, Zwaginga J J, de Haas M. *British Journal Haematology*, 2018, 182:423-426
4. Fetal and Neonatal Alloimmune Thrombocytopenia: Advances in Laboratory Diagnosis and Management. Brouk H, Ouelaa H. *Int. J Blood Res Disord* 2015; 2: 1-6
5. Post-Transfusion Purpura: Current Perspectives. Hawkins J, Aster R H, Curtis B R. *Journal of Blood Medicine* 2019;10:405-415
6. Platelet antibodies in immune thrombocytopenia and related conditions. Kiefel V. *J Lab Med* 2020; 44(5):273-284